Image

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers

Recruiting
18 - 55 years of age
Male
Phase 1

Powered by AI

Overview

The objective of this study is to assess the safety and tolerability of single ascending doses of inhaled CHF10073 (Part 1 of the study) and multiple ascending doses of CHF10073 (Part 2 of the study). The study will also evaluate the PK profile of study drug in plasma and urine after single and repeated administrations of CHF10073.

In addition, this study will also investigate the metabolites profile of CHF10073 in plasma, urine and faeces (Part 2 of the study) and the PK profile of CHF10073 in the lungs after bronchoalveolar lavage (BAL) (Part 3 of the study).

Eligibility

Inclusion Criteria:

  • Subject's written informed consent;
  • Healthy males aged 18-55 years;
  • Understanding of the study procedures and the correct use of the inhalers;
  • BMI between 18.5 and 30.0 kg/m2;
  • Non- or ex-smokers (<5 pack-years and stopped smoking >1 year prior to screening);
  • Good physical and mental status;
  • Vital signs within normal limits; body temperature <37.5°C;
  • 12-lead digitised ECG in triplicate considered as normal;
  • Lung function measurements within normal limits;
  • Males with pregnant or non-pregnant WOCBP partners must be willing to use contraception

Exclusion Criteria:

  • Recent participation in another clinical trial;
  • Clinically significant abnormal 24h Holter ECG (Part 1 and 2);
  • Clinically relevant and uncontrolled medical disorders ;
  • Subjects with history of respiratory diseases ;
  • Presence of any current or recent infection;
  • Clinically relevant abnormal laboratory values;
  • Abnormal liver enzymes;
  • Positive results from the Hepatitis serology results;
  • Positive HIV-1 or HIV-2 serology results ;
  • Recent blood donation or blood loss (≥450 mL) ;
  • Heavy caffeine drinker ;
  • Recent use of any kind of electronic smoking devices;
  • Documented history of alcohol abuse within 12 months prior to screening ;
  • Documented history of drug abuse within 12 months prior to screening ;
  • Intake of non-permitted concomitant medications ;
  • Known intolerance and/or hypersensitivity to any of the study excipients ;
  • Unsuitable veins for repeated venipuncture;
  • Part 3 only: contraindication to the BAL procedure;
  • Part 3 only: recent lower respiratory tract infections

Study details

Pulmonary Fibrosis

NCT06746064

Chiesi Farmaceutici S.p.A.

30 January 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.